Sorrento Collaborates with Celularity to Initiate the Development of Emergency Allogeneic Natural Killer Cell Therapy for Coronavirus Infection
Shots:
- The companies will utilize Celularity's CYNK-001 as a potential novel therapy for the treatment and prevention of coronaviruses targeting mainly 2019-nCoV
- Sorento will utilize its existing “state-of-the-art” cGMP cell therapy manufacturing facilities in California to augment Celularity's new cGMP facility in New Jersey. The combined capacity will boost the scale-up and sustained production of the novel cell therapy
- Celularity's CYNK-001 is an allogeneic- off-the-shelf- placental-derived NK cell therapy. Additionally- Sorrento is in contact with scientists and local Chinese experts to discuss the clinical validation and logistics requirements to fast-track CYNK-001 available in China for coronavirus infection
Click here to read full press release/ article | Ref: Sorrento Therapeutics | Image: Sorrento Therapeutics
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com